QIAGEN N.V. Annual Report 2001

EXECUTIVE OFFICERS AND SUPERVISORY DIRECTORS
62
Supervisory Directors and Managing Directors are appointed annually for the period beginning on the date following
the Annual General Meeting up to and including the date of the Annual General Meeting held in the following fiscal
year. The Supervisory Directors, Managing Directors and executive officers of the Company, and their ages as of
February 15, 2002, are as follows:
Name Age Position
Dr. Metin Colpan 47 Managing Director, Chief Executive Officer
Peer M. Schatz 36 Managing Director, Chief Financial Officer
Prof. Dr. Detlev H. Riesner(1) 60 Chairman of the Supervisory Board, Supervisory Director
Jochen Walter(2) 54 Supervisory Director
Dr. Franz A. Wirtz(1) 69 Supervisory Director
Erik Hornnaess 64 Supervisory Director
Dr. Heinrich Hornef (2) 70 Deputy Chairman of the Supervisory Board, Supervisory Director
Prof. Dr. Manfred Karobath 61 Supervisory Director
Prof. Dr. jur Carsten P. Claussen was appointed as non-voting Special Advisor and Honorary Chairman in 1999.
(1) Member of the Compensation Committee.
(2) Member of the Audit Committee.
The Company has not entered into contracts with any member of the Supervisory Board that provide for benefits upon
a termination of the employment of service of the member.
The following is a brief summary of the background of each of the Supervisory Directors, the Managing Directors and
the Honorary Chairman. Supervisory Directors and Managing Directors are appointed annually for the period
beginning on the day following the Annual General Meeting up to and including the date of the Annual General
Meeting held in the following fiscal year. References to ”QIAGEN” and the ”Company” in relation to periods prior
to April 29, 1996 mean QIAGEN GmbH and its consolidated subsidiaries:
Dr. Metin Colpan is a co-founder of the Company and has been Chief Executive Officer and a Managing Director since
1985. Dr. Colpan obtained his Ph.D. and M.Sc. in Organic Chemistry and Chemical Engineering from the Darmstadt
Institute of Technology in 1983. Prior to founding QIAGEN, Dr. Colpan was an Assistant Investigator at the Institute
for Biophysics at the University of Düsseldorf. Dr. Colpan has had wide experience in separation techniques and in
the separation and purification of nucleic acids in particular, and has filed many patents in the field. Dr. Colpan
currently serves as a supervisory board member of GPC Biotech AG and Ingenium Pharmaceuticals AG, each in
Munich, Germany, and Omnitron in Düsseldorf, Germany. The Company has obtained a key man life insurance
policy on the life of Dr. Colpan in the amount of EUR 767,000.
Peer M. Schatz joined the Company as Chief Financial Officer in 1993 and became a Managing Director in 1998.
Mr. Schatz was previously a partner in a private management buyout group in Switzerland and worked in finance
and systems positions in Sandoz, Ltd. and Computerland AG as well as in finance, operations, management and
sales positions in various start-up companies in the computer and software trading industry in Europe and the United
States. Mr. Schatz graduated from the University of St. Gall, Switzerland, with a Master’s degree in Finance in 1989
and obtained an M.B.A. in Finance from the University of Chicago Graduate School of Business in 1991. Mr. Schatz
also serves in the capacities of director and vice chairman to Evotec OAI AG and Mulligan BioCapital AG and is a
member of the Advisory Board (Börsenrat) of the Frankfurt Stock Exchange.
Professor Dr. Detlev H. Riesner is a co-founder of QIAGEN. He has been on the Company’s Supervisory Board since
1984 and was appointed Chairman of the Supervisory Board in 1999. Professor Riesner has held the Chair of
Biophysics at the Heinrich-Heine-University in Düsseldorf since 1980. In 1996, he was also appointed to the position
of Vice President of Research, and in 1999, he was nominated Director of Technology at the University of Düsseldorf.
Prior to that he was Professor of Biophysical Chemistry at the Darmstadt Institute of Technology and from 1975 to